Web Exclusive. Annals On Call - Regulatory T Cells: Treatment for COVID-19?

Abstract

Web Exclusives1 September 2020Annals On Call - Regulatory T Cells: Treatment for COVID-19?FREERobert M. Centor, MD and Franco R. D’Alessio, MDRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this author and Franco R. D’Alessio, MDJohns Hopkins University School of Medicine, Baltimore, Maryland (F.R.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A19-0037 CME/MOC SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor discusses the potential use of regulatory T cells to treat patients with acute respiratory distress syndrome associated with COVID-19 with Dr. Franco R. D’Alessio.Annals articles discussed include...Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports: https://www.acpjournals.org/doi/10.7326/L20-0681About Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Johns Hopkins University School of Medicine, Baltimore, Maryland (F.R.D.)Disclosures: Dr. Centor has disclosed the following: Consultancy: DynaMed, MDCalc, Medscape, National Kidney Foundation, The Curbsiders. Employment: U.S. Department of Veterans Affairs. Dr. D’Alessio has disclosed the following: Employment: Johns Hopkins University School of Medicine. Research grants/contracts: NHLBI R01 HL131812. Patent owner: Patent C13113_P13113-04—U.S. patent application no. 15/542,380 Compositions and Methods to Accelerate Resolution of Acute Lung Inflammation pending.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interests to disclose. Eliseo Guallar, MD, MPH, DrPH, Deputy Editor, Statistics, reports that he has no financial relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRegulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports Douglas E. Gladstone , Bo Soo Kim , Kathy Mooney , Andrew H. Karaba , and Franco R. D'Alessio Metrics 1 September 2020Volume 173, Issue 5Page: OC1KeywordsAcute respiratory distress syndromeCOVID-19DisclosureHealth careKidneysPatientsPneumoniaResearch grantsRespiratory system proceduresT cells ePublished: 1 September 2020 Issue Published: 1 September 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.Loading ...